Incyte Corp (INCY) Stock Price, Quote & News

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 498 6700

Website: www.incyte.com

Address:

1801 Augustine Cut-Off, Wilmington, United States

BioTuesdays Apr. 2 at 12:49 PM

$ADAG and Incyte $INCY have announced a clinical collaboration to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC) with or without liver metastases. https://biotuesdays.com/2026/04/02/adagene-and-incyte-collaborate-to-evaluate-combination-therapy-in-mss-crc-patients/

0 · Reply

Nomorelies Mar. 31 at 11:33 PM

$INCY

0 · Reply

TradingFUD Mar. 31 at 10:35 PM

$SNDX In studies like [AGAVE-201], axatilimab showed high response rates in patients who had already failed other treatments, including Jakafi. $INCY has the cash to buy $SNDX.

0 · Reply

TradingFUD Mar. 31 at 10:31 PM

$SNDX In studies like [AGAVE-201], axatilimab showed high response rates in patients who had already failed other treatments, including Jakafi. $INCY has the cash to buy $SNDX.

0 · Reply

Night_Owl_Biotech Mar. 31 at 1:09 AM

$SNDX share price since 12/10/25. It's been a great run for SNDX since last summer when SNDX was trading for less than $10/share At the same time, SNDX's share price is still down 10% from the summer of 2024 when Niktimvo was first approved, while the $XBI has been up ~20%. Back to the last 4 months, while roughly half of SNDX's 92 peer comm'l-stage bios are off 25% or more from recent highs since early December, SNDX had fared very well. However, SNDX traded meaningfully lower today. This is more or less inconsistent with its recent trading pattern since early December 2025. We certainly hope it is not a trend. SNDX continues to be the #1 holding of our investment club. However, the brutal truth is SNDX FY2029 (aka Year 4) analyst estimates have been coming down since early December 2025. Recall Centerview Partners noted $SWTX peer Year 4 M&A revenue multiples averaged 3.8X (but were as low at 2.3X and as high as 5.0X). This is not investment advice. $IBB $INCY

0 · Reply

fillzane Mar. 29 at 5:04 PM

$INCY DVLT gets more interesting the deeper you go into the numbers. FY2025 revenue reached $39.1M, up 1,362% YoY from $2.7M in FY2024. Gross profit climbed to $30.4M, and gross margin hit 78%, which is what makes this story different from lower-quality small caps that can grow but still cannot convert that growth into attractive economics. On top of that, the company reported its first profitable quarter, then reiterated a 2026 revenue target of at least $200M. If the market starts to believe that RWA, data monetization, and exchange infrastructure are converging into one scalable business model here, the rerating argument gets a lot easier to understand. It is not just a huge TAM story anymore; it is becoming a margin-plus-growth story too.

4 · Reply

DonCorleone77 Mar. 29 at 3:48 PM

$INCY Incyte announces new 54-week data on safety, efficacy of povorcitinib Incyte announced 54-week data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients with moderate to severe hidradenitis suppurativa, HS. The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology, AAD, Annual Meeting, being held March 27-31, 2026, in Denver. "The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS," said Pablo Cagnoni, M.D., President and Global Head of Research and Development, Incyte. "Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical benefit with a manageable safety profile, underscoring its promise to help transform the HS treatment landscape as the first oral option. We look forward to advancing our regulatory applications in the U.S. and Europe."

0 · Reply

Doozio Mar. 26 at 6:53 PM

$INCY wincy NXT?

0 · Reply

Night_Owl_Biotech Mar. 26 at 12:10 AM

This is not investment advice because we have no idea what $SNDX might be worth in a hypothetical M&A exit. The attachment compares SNDX 7-year (FY26-FY32) analyst consensus revenue ests against mgmt/BOD prepared 7-year revenue forecasts from 11 recent peer commercial-stage bio M&A exits. Analysts forecast SNDX to generate more revenues over the next 7 years than CCXI & AAAP mgmt/BOD prepared revenue forecasts when they were acquired for enterprise values ("EV") of $3.7B & $3.9B, respectively. CCXI projected 91% gross margins where SNDX actual FY25 gross margins were 96%. SWTX mgmt/BOD prepared revenue forecasts were ~20% higher than analysts forecast for SNDX (though @ lower gross margins). SWTX was acquired for an EV of $3.4B. We do not know if SNDX analyst estimates are accurate nor credible. We're curious what SNDX investors believe would consider an adequate M&A exit EV for SNDX using these data points (or any others)? Is $FOLD an absolute ceiling? $INCY $XBI $IBB @flanker30 @JFais

0 · Reply

JFais Mar. 25 at 6:58 PM

$SNDX (L) Good Chat thread on M&A comps in oncology space given today's $TERN news $INCY clearly needs the revs Niktimvo + Revuforj could provide, just a question of timing & whether Syndax gets too big for them Putting on my skeptical hat, I think it goes for $35 to $40 if bought out today (if shareholders get screwed). Reasonable would be $45 -$50 If we wait for IPF and frontline AML data (ven/aza triplet), rises to $60+ (if high MRD rate holds up along with manageable AEs)

2 · Reply

Incyte's skin disease drug shows long-term symptom relief in late-stage trials

Mar 28, 2026, 3:00 PM EDT - 8 days ago

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 25, 2026, 9:00 AM EDT - 11 days ago

Incyte Announces Executive Leadership Appointments

Mar 22, 2026, 11:11 PM EDT - 13 days ago

Incyte: An Undervalued Healthcare Gem

Mar 20, 2026, 10:00 AM EDT - 16 days ago

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 17, 2026, 10:24 AM EDT - 19 days ago

Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue

Mar 17, 2026, 7:30 AM EDT - 19 days ago

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

Mar 17, 2026, 7:30 AM EDT - 19 days ago

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

Mar 16, 2026, 3:55 PM EDT - 20 days ago

Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond

Mar 11, 2026, 11:02 AM EDT - 25 days ago

Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 12:10 PM EDT - 26 days ago

Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 6, 2026, 4:42 PM EST - 4 weeks ago

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Mar 2, 2026, 2:57 PM EST - 4 weeks ago

Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 27, 2026, 8:11 AM EST - 5 weeks ago

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

LLY

Feb 18, 2026, 10:38 PM EST - 6 weeks ago

Incyte Remains Undervalued As Opzelura And Niktimvo Scale

Feb 17, 2026, 8:00 AM EST - 6 weeks ago

Incyte to Present at Upcoming Investor Conferences

Feb 13, 2026, 5:45 AM EST - 7 weeks ago

Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells

ASML BABA BEKE BEPC GOOG GOOGL LULU

Feb 11, 2026, 11:03 AM EST - 7 weeks ago

Incyte: Why The Market Is Overreacting To A Guidance 'Miss'

Feb 10, 2026, 3:44 PM EST - 7 weeks ago

Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript

Feb 10, 2026, 8:13 AM EST - 7 weeks ago

Incyte weak 2026 revenue forecast heightens Jakafi patent concerns

Feb 10, 2026, 7:00 AM EST - 7 weeks ago

Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

Jan 30, 2026, 9:29 AM EST - 2 months ago

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Jan 27, 2026, 8:00 AM EST - 2 months ago

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

Jan 22, 2026, 2:37 AM EST - 2 months ago

What Investors Should Know Before Buying Incyte

Jan 16, 2026, 1:34 PM EST - 2 months ago

Incyte: Buy For The Turnaround, Stay For The Pipeline

Jan 16, 2026, 8:15 AM EST - 2 months ago

Incyte's Pipeline Potential Signals Massive Upside For Investors

Jan 15, 2026, 11:00 AM EST - 2 months ago

Steven Cress' Top 10 Stocks For 2026

ABX ALL AMD ATI B CIEN CLS

Jan 13, 2026, 6:02 PM EST - 2 months ago

Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity

Jan 12, 2026, 2:55 PM EST - 2 months ago

Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 2:18 PM EST - 3 months ago

Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins

Jan 6, 2026, 1:30 PM EST - 3 months ago

Top 10 Stocks For 2026

ALL AMD ATI B CIEN CLS COHR

Jan 5, 2026, 11:59 AM EST - 3 months ago

Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer

Jan 5, 2026, 7:40 AM EST - 3 months ago

Incyte's blood cancer therapy meets main goal in late-stage trial

Jan 5, 2026, 7:30 AM EST - 3 months ago

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma

$Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma$

Dec 22, 2025, 2:44 AM EST - 3 months ago

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

Dec 22, 2025, 2:42 AM EST - 3 months ago

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

Dec 18, 2025, 8:30 AM EST - 3 months ago

Best Defensive Stocks To Balance Tech Sector Volatility

BIP MU RSP VRTX XLK

Dec 18, 2025, 8:00 AM EST - 3 months ago

Incyte to Present at Upcoming Investor Conference

$Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma$

Dec 17, 2025, 11:20 AM EST - 3 months ago

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Dec 12, 2025, 8:30 AM EST - 4 months ago

Incyte Announces Change to its Board of Directors

Dec 9, 2025, 12:59 PM EST - 4 months ago

Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack

NFLX SHAK TMO

Dec 8, 2025, 4:30 PM EST - 4 months ago

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

Dec 7, 2025, 6:23 PM EST - 4 months ago

Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript

Dec 7, 2025, 9:30 AM EST - 4 months ago

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Dec 7, 2025, 9:30 AM EST - 4 months ago

Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Dec 6, 2025, 9:00 AM EST - 4 months ago

Incyte: Buy At This Inflection Point

Dec 3, 2025, 4:30 PM EST - 4 months ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 3:13 PM EST - 4 months ago

Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 8:00 AM EST - 4 months ago

Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo

Dec 2, 2025, 2:03 PM EST - 4 months ago

Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

BioTuesdays Apr. 2 at 12:49 PM

0 · Reply

Nomorelies Mar. 31 at 11:33 PM

$INCY

0 · Reply

TradingFUD Mar. 31 at 10:35 PM

$SNDX In studies like [AGAVE-201], axatilimab showed high response rates in patients who had already failed other treatments, including Jakafi. $INCY has the cash to buy $SNDX.

0 · Reply

TradingFUD Mar. 31 at 10:31 PM

$SNDX In studies like [AGAVE-201], axatilimab showed high response rates in patients who had already failed other treatments, including Jakafi. $INCY has the cash to buy $SNDX.

0 · Reply

Night_Owl_Biotech Mar. 31 at 1:09 AM

0 · Reply

fillzane Mar. 29 at 5:04 PM

4 · Reply

DonCorleone77 Mar. 29 at 3:48 PM

0 · Reply

Doozio Mar. 26 at 6:53 PM

$INCY wincy NXT?

0 · Reply

Night_Owl_Biotech Mar. 26 at 12:10 AM

0 · Reply

JFais Mar. 25 at 6:58 PM

2 · Reply

Doozio Mar. 25 at 5:08 PM

$INCY is it as easy as a TERNaround Tuesday off da 200d to da nipple? 🐒🍌🧠⏰♾️

0 · Reply

2_logs_higher Mar. 21 at 11:26 PM

$INCY according to meta AI, hopefully, any day now we see an approval. We sure could use a change in the direction of the stock price.

0 · Reply

2_logs_higher Mar. 17 at 7:26 PM

$INCY Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ANVISA, the Brazilian health regulatory agency, for an additional indication for MINJUVI® (tafasitamab). Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ: INCY) in 2021 for tafasitamab (commercialized as MONJUVI® (tafasitamab-cxix) in the United States and MINJUVI® ex-USA) across Latin America. Knight has launched MINJUVI® in Brazil, Mexico and Argentina for use in combination with lenalidomide followed by MINJUVI® monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLCBL arising from low grade lymphoma in Brazil, who are not eligible for autologous stem cell transplantation (ASCT). https://finance.yahoo.com/news/knight-therapeutics-announces-approval-additional-113000997.html

0 · Reply

zman94 Mar. 16 at 11:36 PM

https://seekingalpha.com/article/4882856?gt=4f71e89bf7fe3dec $INCY

0 · Reply

erevnon Mar. 16 at 2:24 PM

Jefferies downgrades Incyte $INCY from Buy to Hold and lowers the price target from $120 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Night_Owl_Biotech Mar. 14 at 9:46 PM

Attached see $SNDX valuation, analyst revenue estimates & related multiples compared to $DAWN 's M&A exit valuation. If DAWN's market cap (post M&A announcement) is now 1.03X DAWN 5-year analyst consensus, would SNDX command a higher 5-year multiple than 1.03X in a hypothetical M&A exit (excluding cash/debt) because; 1. SNDX revenues generated higher gross profit margins than DAWN in FY2025 (SNDX 96% to DAWN 90%)? 2. SNDX revenues come from 2 FDA approved therapies compared to DAWN's 1 FDA approved therapy (in theory lowering risk to an acquirer)? 3. SNDX 2 products both appear to have longer patent lives (Niktimvo FY36, Revuforj 6/8/37) than DAWN's Ojemda (June 35)? We're only asking the question. This is not investment advice. $INCY $XBI $IBB

2 · Reply

SuperGreenToday Mar. 13 at 1:47 PM

$INCY Share Price: $92.63 Contract Selected: Sep 18, 2026 $95 Calls Buy Zone: $11.90 – $14.69 Target Zone: $21.96 – $26.83 Potential Upside: 74% ROI Time to Expiration: 188 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

southerndude Mar. 10 at 5:17 PM

$TGTX TG could end up being the next $INCY Everyone thought they would be bought out in early years with their flagship product, Jakafi, quickly ramped up to blockbuster and beyond with big profits, but eventually rumors died out and it became an anomaly- GIA with a blockbuster. Long term you would have made some money over the 15 years since launch, but missed all the other opportunities during that time (including an easy SP index fund). Incyte never really produced another product with substantial revenues and they’re still riding Jakafi into its final days. Now the stock price bounces up and down, but no real excitement or growth beyond the ups/downs for earnings calls and occasional study updates. TG is not the next Seagen or Celgene…. Sell it now MW

2 · Reply

Night_Owl_Biotech Mar. 10 at 1:38 AM

$SNDX 7-year analyst consensus revenue estimates (FY26 - FY32 reflected as Year 1 to Year 7) compared to the 7-year revenue forecasts prepared by the mgnt/BOD of 14 SNDX peers who exited via M&A. It is interesting to note analysts project SNDX to generate slightly more revenue dollars over the next 7 years as CCXI & AAAP products after their M&A exits. Both were acquired for enterprise values ("EV") of just under $4B. Does this suggest SNDX would be worth roughly $4B in EV in a M&A exit? If SNDX generates high gross profit margins on the revenues than CCXI, does that suggest SNDX's hypothetical M&A EV is even higher? NPSP mgnt/BOD prepared 7-year revenue forecasts were slightly higher than analyst's forecast for SNDX. NPSP was acquired for $5.2B in EV (NPSP was acq at a time when there were far fewer comm'l-stage bios to acquire so the acquirer may have paid a premium). These are questions, not investment advice. We're genuinely curious how SNDX investors read the comps $XBI $IBB $INCY

1 · Reply

ZacksResearch Mar. 9 at 5:52 PM

$INCY just secured a major EU milestone — and it opens a brand-new treatment lane. Zynyz won EC approval with chemotherapy for advanced anal cancer, marking the first systemic treatment option for this indication and expanding the drug’s reach in oncology. 💊 Discover what this approval could mean for the company 👉 https://www.zacks.com/stock/news/2881109/incy-wins-ec-approval-for-label-expansion-of-oncology-drug-zynyz?cid=sm-stocktwits-2-2881109-teaser-36623&ADID=SYND_STOCKTWITS_TWEET_2_2881109_TEASER_36623

0 · Reply

ZacksResearch Mar. 9 at 4:52 PM

$INCY up 34.4% in a year compared to the industry’s 12.5% growth — what’s driving the surge? 🚀 The European Commission just approved Zynyz for a second indication, marking a major expansion in their oncology portfolio. This approval comes after a study showed a 37% reduction in risk of progression or death for patients with metastatic or inoperable SCAC not previously treated with systemic chemotherapy. Discover the full story here 👉 https://www.zacks.com/stock/news/2881109/incy-wins-ec-approval-for-label-expansion-of-oncology-drug-zynyz?cid=sm-stocktwits-2-2881109-body-36592&ADID=SYND_STOCKTWITS_TWEET_2_2881109_BODY_36592

0 · Reply

2_logs_higher Mar. 7 at 2:06 AM

$AGEN & $INCY an inside joke, but what does incy know?

1 · Reply

Market Cap	19.09B
Revenue (ttm)	5.14B
Net Income (ttm)	1.29B
EPS (ttm)	N/A
PE Ratio	16.29
Forward PE	14.43
Profit Margin	25.03%
Debt to Equity Ratio	0.00

Volume	1,160,000
Avg Vol	1,770,092
Day's Range	N/A - N/A
Shares Out	199.01M
Stochastic %K	98%
Beta	0.85
Analysts	Sell
Price Target	$109.14